Effect of PCSO-524 on OA Biomarkers and Weight Bearing Properties in Canine Shoulder and Coxofemeral Osteoarthritis

This trial included 66 mixed breed dogs with x-ray confirmed OA split into two treatment groups for 24 weeks. These were 1) PCSO-524 (5 mg/kg) and 2) fish oil (2,000 mg/d). The dogs were all placed on a standardised diet to minimise variability.

The results suggest that PCSO-524 is protective against cartilage breakdown in dogs with osteoarthritis.

. . . VIEW

. . . VIEW

Application of the Polyunsaturated fatty acid compound PCSO-524 in the post operative recovery of dogs that have had stifle surgery

WSAVA FASAVA Congress 2013
World Small Animal Veterinary Assoc.
38th Annual Congress 6-9 March 2013, Auckland, New Zealand

The clinical outcomes of the use of PCSO-524 in 28 dogs that had undergone surgery on the stifle (which included correction of the patellar luxation and correction of cranial cruciate ligament rupture) were studied at the Small Animal Teaching Hospital, at Chulalongkorn University, Bangkok, Thailand.

Twenty-eight dogs that undergone both stifle surgery were included in our study. All test subjects had been given pre-emptive analgesia (morphine sulfate). NSAIDs and glucosamine had been administered before the surgery.

Two postoperative treatments were:

  1. NSAIDs treatment for one week in combination with glucosamine sulfate;
  2. only PCSO-524 treatments.

 

 

. . . VIEW

 

. . . VIEW

Chronic pain is commonly caused by degenerative disease, which is under diagnosed in cats.

PCSO-524 is an extract of Perna canaliculus, a known source of Omega-3 polyunsaturated fatty acids (PUFAs) with anti-inflammatory properties. Lipids extracted from the New Zealand green-lipped mussel (NZGLM) contain a complex mixture of mainly phospholipids (PL, 57-79%), triglycerides (TG, 10-25%), free fatty acids (FFA, 7-12%) and sterols (ST, 12-18%)

PCSO-524 is a source of omega-3 polyunsaturated fatty acids with anti-inflammatory properties commonly used to treat osteoarthritis in human beings and dogs.

The purpose of this study was to study the effects of PCSO-524 extract on vital signs, completed blood count, and blood chemistry in clinically-healthy normal cats.

 

 

. . . VIEW

. . . VIEW

The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.

Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.

All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.

 

. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted

 

Discover More Studies
Click to see the digital library